CG Oncology (NASDAQ:CGON) Receives Overweight Rating from Cantor Fitzgerald

CG Oncology (NASDAQ:CGON)‘s stock had its “overweight” rating restated by equities researchers at Cantor Fitzgerald in a report issued on Thursday, Benzinga reports. They presently have a $75.00 price target on the stock. Cantor Fitzgerald’s target price points to a potential upside of 86.52% from the company’s previous close.

Several other equities research analysts also recently weighed in on CGON. Morgan Stanley started coverage on CG Oncology in a report on Tuesday, February 20th. They set an “overweight” rating and a $55.00 price target for the company. The Goldman Sachs Group began coverage on shares of CG Oncology in a research report on Tuesday, February 20th. They set a “neutral” rating and a $42.00 target price on the stock. Finally, HC Wainwright restated a “buy” rating and set a $75.00 price objective on shares of CG Oncology in a report on Thursday, April 4th.

CG Oncology Price Performance

Shares of CG Oncology stock traded down $0.41 on Thursday, hitting $40.21. 125,032 shares of the company were exchanged, compared to its average volume of 607,875. CG Oncology has a 1-year low of $28.55 and a 1-year high of $50.23. The stock’s 50-day moving average is $39.91.

Hedge Funds Weigh In On CG Oncology

An institutional investor recently bought a new position in CG Oncology stock. BNP Paribas Financial Markets acquired a new position in CG Oncology, Inc. (NASDAQ:CGON) in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 11,198 shares of the company’s stock, valued at approximately $492,000. 26.56% of the stock is owned by institutional investors.

CG Oncology Company Profile

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.